CEOs successfully navigating data readouts often follow a predictable playbook: Assembling a cross-functional “war room”, sequencing stakeholder communications strategically, and anchoring new narratives in scientific truth rather than the spin. Companies with contingency messaging frameworks prepared before readouts consistently outperform those that scramble after.

Biotech companies have a habit of building stories around anticipated data. The pitch deck starts as the proposal, the investor calls in on the hint, and the community hopes for the best. Unfortunately, when the data finally does arrive, it is wrong more often than not.

So, how do you survive in those pivotal moments, ultimately saving yourself from the spiral? It all comes down to the mechanics of a narrative shift.

Included below are patterns drawn from industry case studies, public disclosures, investor call transcripts, and documented communication strategies from companies that have navigated these exact scenarios from 2024 to 2025.

The Initial Narrative

Amylyx developed a treatment for ALS called Relyvrio, a drug approved by the FDA in September 2022. The drug propped up the patient community as a hopeful option, and the company committed to something rather rare: voluntarily withdrawing the drug if confirmatory phase three trials failed.

What Changed

But, by March 2024, the PHOENIX trials resulted in catastrophically low success. Relyvrio failed to beat placebo trials on both primary and secondary endpoints.

The After Narrative

Amylyx had a lot to prove with the rather astonishing promise, and within one week of the data readout, they had announced that they would voluntarily remove Relyvrio from all Canadian and U.S. markets. Their messaging focused on three anchors:

• • • • Honoring the commitment: In the original trials, they stated that if PHOENIX was not successful, they would do what was right by the patients and voluntarily remove the product. The new line became focused on changing course, doing right by the stakeholders instead of standing by their product despite the results.
      • Protecting current patients: Amylyx focused primarily on creating a free drug program for patients who wanted to continue the treatment while maintaining a patient-first narrative.
      • Pipeline continuity: Amylyx put an immediate emphasis on AMX0035’s potential in Wolfram syndrome and progressive supranuclear palsy, plus AMX0114 for ALS.

Timeline

On day one, Amylyx provided the data readout, and within one week, they provided a market withdrawal announcement. In the second week, Wolfram syndrome was mentioned as showing positive signals.

Three months later, Amylyx was back in the news when it announced its acquisition of avexitide, its introduction into the GLP-1 space.

What Worked

Sticking to the prior public commitment to create credibility. Others within the industry considered its action worthy of praise, especially considering most companies find loopholes to acquit themselves when things go wrong. Finally, quickly shifting to the GLP-1 space showed that the company wasn’t paralyzed.

All the while, Amylyx avoided words like “failure,” “setback,” and “surprised,” and instead relied on phrases like “informed by results,” “committed to patients,” and “paths forward.”

The Initial Narrative

Agios Pharmaceuticals spent over a decade working on its identity as a cancer company. They had created two oncology drugs (Tibsovo and Inhifa) and a robust cancer pipeline. The company focused primarily on the idea of cellular metabolism meeting precision oncology.

What Changed

At the beginning of 2019, internal analysis revealed that the company’s pyruvate kinase (PK) activation platform had potentially larger, more defensible opportunities in rare genetic blood diseases than in the crowded oncology market. The company had, in the past, received criticism for providing many promises with few returns.

The After Narrative

In December 2020, Agios announced that it would sell its entire oncology portfolio, which included two marketed drugs, to France’s Servier for $1.8 billion. The shift focused on changing the narrative from “oncology innovator” to “rare disease leader.”

The Messaging Infrastructure

The quick change was branded as the result of long-term planning rather than pivoting into a new market because of failure. The key messaging elements included the following:

• • • • Platform continuity: Rhetoric inside the company doubled down on its commitment to cellular metabolism. However, when they made the switch, the narrative updated to their commitment to a research platform that saw mechanisms applicable outside of oncology.
      • Financial strength: The $1.8 billion cash position served as the launching point for a strategic pivot instead of relying on desperate last-minute decisions.
      • Immediate milestones: The Pyrukynd approval in February 2022 for PK deficiency by the FDA validated the decision for a new direction within 18 months.

Timeline

In the final quarter of 2020, Agios Pharmaceutical announced its oncology sale, quickly followed by a shift to Sevier in the second quarter of 2021. They quickly released our product for a rare disease (Pyrukynd). Finally, and most recently, AVESME was approved for thalassemia, cementing their new infrastructure.

What Worked

The sale in 2019 proved the pivotal point in Agios Pharmaceutical’s transformation. It signaled to investors that it had returned to a profitable company that could produce biotechnological products through careful pivoting.

The Initial Narrative

Vertex had built a $500+ billion company on cystic fibrosis medications, but quickly pivoted its direction to diversify beyond a single therapeutic area. The paint program was a high-risk, high-reward bet on a notoriously difficult space where dozens of companies had already failed.

What Changed

In January 2024, Phase 3 results for VX-548 showed statistically significant and clinically meaningful pain reduction compared to the placebo trials. The drug was extremely effective in rapid and moderate-to-severe pain relief, showing a wide range of uses in both surgical and non-surgical pain conditions.

The positive data had its own messaging complexity, including questions about how to scale communications without overpromising, how to address the problem that VX-548 still didn’t beat out hydrocodone in the key secondary endpoint, and how to maintain credibility with investors worried about the opioid crisis.

The After Narrative

The new narrative focused on finding a middle ground between traditional, low-effect pain relievers and opioids. The key messaging included the following:

• • • • Scientific humility limitations: The press agents for the company were transparent that the drug didn’t beat opioids in all measures, but instead positioned it as a different solution.
      • Regulatory pathway clarity: The FDA Breakthrough Therapy designation showed its compliance with regulatory requirements.
      • Pipeline expansion: The immediate follow-up was an announcement of phase two studies in neuropathic pain conditions.

Timeline

In rapid succession, on January 30th, 2024, Phase 3 was announced, and a same-day conference call provided detailed data presentations. In the second quarter of 2024, Vertex rolled out submissions. Finally, at the end of 2024, suzetrigine became the first new class of pain medicine in two decades.

What Worked

Vertex had prepared multiple messaging scenarios in advance. The targeted and nuanced data required predetermined language that acknowledged limitations while emphasizing the meaningful clinical advance.

Industry leaders now need messaging prepared in advance that follows “message maps,” which include some of the following elements:

Stakeholder Sequence

Board → Employees → Investors (simultaneous press) → Media

Board → Investors → Employees → Media

Board → Employees → Investors → Media

Board → Employees → Patients → Investors → Media

Industry best practices documented by investor relations firms within the biotech sector have said this is the proper timeline when switching messaging quickly:

• • • • Hour 0-4: Data review with scientific team, including preliminary interpretation
      • Hour 4-12: Legal or regulatory consultation on disclosure timing and requirements
      • Hour 12-24: Executive team alignment on messaging and draft communications
      • Hour 24-48: Board notification and employee briefing presentation
      • Hour 48-72: Investor call scheduling, press release finalization, and stakeholder execution

Spokesperson Training

Companies that navigate data pivots successfully usually invest in the following:

• • • • Scenario rehearsals: Running mock Q&A sessions for positive, negative, and ambiguous outcomes.
      • Bridge statements: Teaching executives to acknowledge questions while returning to key messages.
      • Silence discipline: Training on what NOT to say, including avoiding speculation about competitor comparisons or future regulatory decisions.

How quickly do CEOs need to respond after disappointing clinical trial results?

Most public companies should provide disclosure requirements within the first 24-48 hours. But the most important aspect is providing quality responses. Companies that take 72 hours to deliver a clear, coordinated message usually have better results than those that rush in with incomplete statements after 24 hours. The key is to have contingency frameworks prepared before results arrive.

Who should be involved in crafting the new narrative after a data pivot?

The core team and those decisions usually include the CEO (as the primary spokesperson), the Chief Medical Officer (for scientific credibility), the Chief Financial Officer (for investor-related messaging), the General Counsel (for disclosure compliance), and the Head of Investor Relations (for stakeholder sequencing). For anything involving patient-facing therapies, add a patient advocacy liaison to make sure the patient community isn’t blindsided. Scientific founders provide credibility, but make sure they are coached on investor-appropriate language.

What’s the biggest mistake companies make when messaging through disappointing data?

The most common failures are associated with excuses or scientific rationale before knowing the impact on stakeholders. Investors and patients want to know what happens next, so avoid messaging that explains why the trial design was flawed or why the data were unexpected. Another big mistake is in fragmenting communications. Telling the board one story, employees another, and investors something else creates inconsistencies that destroy credibility faster than bad data.

Should companies prepare multiple messaging scenarios before data readouts?

Absolutely. Industry best practice focuses on four styles: strong positive, meets expectations, mixed/ambiguous, and clear negative. Each style should have its own pre-approved language, stakeholder sequencing, and Q&A preparation. Changes in messaging can make you feel far more in control if you can cover all of your bases.

How do you sequence communications across different audiences after a data pivot?

The typical sequence for significant news flows as follows: Board Of Directors (the first in line before any external communication), employees (before any public announcement to prevent them from learning any data from the media), investors (through a 8-K filing or press release), patients and patient advocacy groups (usually around the same time as investors), and public media (typically through press releases and earned media). Sometimes, negative news requires the company to brief key investors individually before a public announcement to provide context. Keep in mind that this method is legal but can carry risks.

What language choices matter most when the story is changing?

Use action language and patient-centric framing in conjunction with specific next steps within timelines. Some of these examples may include, “We are advancing,” or “Our commitment to patients informed this decision.”

Avoid any passive voice, defensive language, and comparisons to competitors. Some of these examples may include “Results were not as expected,” or “Despite the challenges.”

Biotech companies that navigate data pivots successfully all share some common traits:

• • • • They prepare before they need to. Most of the time, this includes message maps, spokesperson training, and scenario planning before data arrives.
      • They lead with transparency. Acknowledging what didn’t work builds more credibility than explaining why it should have worked.
      • They sequence stakeholder communications deliberately. They focused on the right order: board, employees, investors, then patients.
      • They pivot to action. Every disappointing readout announcement includes specific next steps, whether that’s pivoting the application, doubling down on a subgroup, or redirecting resources to other assets.
      • They protect their people. Companies that treat their employees, investors, and partners well during a pivot show what kind of organization you are.

Inevitably, science changes. When that happens, the story changes with it. The question is whether you’ve built the infrastructure to change it well.

Kepler Script focuses on technical professionals looking to build personal brands that attract clients and establish authority. Ghostwritten books turn your expertise into a tangible asset that opens doors to speaking engagements, media opportunities, and premium client relationships.

Kepler Script also focuses on building long-term marketing systems that keep your name in front of the right people using LinkedIn networking strategies, e-mail newsletters, and ongoing article content. If you’re ready to stop being the best-kept secret in your field, reach out to start a conversation.